TY - JOUR
T1 - The Impact of COVID-19 on Individuals Across the Spectrum of Visual Impairment
AU - Shalaby, Wesam S.
AU - Odayappan, Annamalai
AU - Venkatesh, Rengaraj
AU - Swenor, Bonnielin K.
AU - Ramulu, Pradeep Y.
AU - Robin, Alan L.
AU - Srinivasan, Kavitha
AU - Shukla, Aakriti Garg
N1 - Funding Information:
Funding/Support: Publication of this article was supported by the US National Institutes of health (to Pradeep Y. Ramulu), the American Glaucoma Society (to Alan L. Robin), and an American Glaucoma Society Mentoring for Advancement of Physician Scientists grant (to Aakriti Garg Shukla). Financial Disclosures: Alan L. Robin is an employee of the American Glaucoma Society. Pradeep Y. Ramulu has financial arrangements with Thea Pharmaceuticals, Ivantis, WL Gore, and Perfuse Therapeutics. Alan L. Robin has financial arrangements with Versant Health and Perfuse Therapeutics. Aakriti Garg Shukla has financial arrangements with Allergan. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST and none were reported. Funding/Support: Publication of this article was supported by the US National Institutes of health (to Pradeep Y. Ramulu), the American Glaucoma Society (to Alan L. Robin), and an American Glaucoma Society Mentoring for Advancement of Physician Scientists grant (to Aakriti Garg Shukla). Financial Disclosures: Alan L. Robin is an employee of the American Glaucoma Society. Pradeep Y. Ramulu has financial arrangements with Thea Pharmaceuticals, Ivantis, WL Gore, and Perfuse Therapeutics. Alan L. Robin has financial arrangements with Versant Health and Perfuse Therapeutics. Aakriti Garg Shukla has financial arrangements with Allergan. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/7
Y1 - 2021/7
N2 - Purpose: TO assess perceptions and implications of COVID-19 infection across the spectrum of individuals with visually impairment (VI) and those with normal sight. Design: Prospective cross-sectional comparative study. Methods: Setting: institutional. Patients: 232 patients and their caregivers. Four groups were created based on better eye characteristics: blind (best-corrected distance visual acuity [BCDVA] <3/60 or visual field <10 central degrees); severe VI (BCDVA ≤3/60 to <6/60; vertical cup-to-disc ratio ≥0.85 or neuroretinal rim width ≤0.1); moderate VI (BCDVA ≤6/60 to <6/18); or no or mild VI (controls: BCDVA ≥6/18) based on International Classification of Diseases-10 criteria and Foster and Quigley's consensus definition of glaucoma. Procedure: telephone questionnaires. Main outcome measures: differences in perceptions and implications of COVID-19 infection across various levels of VI. Caregiver perceptions were a secondary outcome measure. Results: Surveys were completed by 232 participants, with 58 participants in each VI group. Mean age was 58.9 ± 13.2 years old. Greater degrees of VI were associated with older age (P = .008) and lower education level (P = .046). Blind participants more commonly perceived vision as a risk factor for contracting COVID-19 (P = .045), were concerned about access to health care (P <.001), obtained news through word of mouth (P <.001), and less commonly wore masks (P = .003). Controls more commonly performed frequent handwashing (P = .001), were aware of telemedicine (P = .029), and had fewer concerns about social interactions (P = .020) than groups with substantial VI. All caregivers reported more frequent patient care since the COVID-19 pandemic began. Conclusions: The pandemic might have had a disproportionate impact on the visually impaired, and evidence-based assessments of COVID-19 health outcomes in this population are warranted.
AB - Purpose: TO assess perceptions and implications of COVID-19 infection across the spectrum of individuals with visually impairment (VI) and those with normal sight. Design: Prospective cross-sectional comparative study. Methods: Setting: institutional. Patients: 232 patients and their caregivers. Four groups were created based on better eye characteristics: blind (best-corrected distance visual acuity [BCDVA] <3/60 or visual field <10 central degrees); severe VI (BCDVA ≤3/60 to <6/60; vertical cup-to-disc ratio ≥0.85 or neuroretinal rim width ≤0.1); moderate VI (BCDVA ≤6/60 to <6/18); or no or mild VI (controls: BCDVA ≥6/18) based on International Classification of Diseases-10 criteria and Foster and Quigley's consensus definition of glaucoma. Procedure: telephone questionnaires. Main outcome measures: differences in perceptions and implications of COVID-19 infection across various levels of VI. Caregiver perceptions were a secondary outcome measure. Results: Surveys were completed by 232 participants, with 58 participants in each VI group. Mean age was 58.9 ± 13.2 years old. Greater degrees of VI were associated with older age (P = .008) and lower education level (P = .046). Blind participants more commonly perceived vision as a risk factor for contracting COVID-19 (P = .045), were concerned about access to health care (P <.001), obtained news through word of mouth (P <.001), and less commonly wore masks (P = .003). Controls more commonly performed frequent handwashing (P = .001), were aware of telemedicine (P = .029), and had fewer concerns about social interactions (P = .020) than groups with substantial VI. All caregivers reported more frequent patient care since the COVID-19 pandemic began. Conclusions: The pandemic might have had a disproportionate impact on the visually impaired, and evidence-based assessments of COVID-19 health outcomes in this population are warranted.
UR - http://www.scopus.com/inward/record.url?scp=85104333105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104333105&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2021.03.016
DO - 10.1016/j.ajo.2021.03.016
M3 - Article
C2 - 33781768
AN - SCOPUS:85104333105
SN - 0002-9394
VL - 227
SP - 53
EP - 65
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -